Listen to our latest episode of ONCOLOGY on The Go with insights from expert multidisciplinary professionals across the oncology space. 

ONCOLOGY On The Go Podcast

CancerNetwork in now on YouTube! We'll be discussing in-depth topics, and speaking with top leaders in the oncology space.

Find Us On YouTube

Your next job in oncology is just a click away! Explore positions across the cancer care industry with CancerNetwork® Oncology Career Center.

CancerNetwork® Oncology Career Center

Get comprehensive coverage for the multidisciplinary oncology community with accurate, credible, and timely news and expert insights.

Subscribe to Our eNewsletter Today!

The September issue of ONCOLOGY features a rare case study on glioblastoma, discussions on end-of-life care, and insights into the field of pediatric oncology. 

September ONCOLOGY Publication

Michael Buckstein, MD, spoke with CancerNetwork about the benefits of using radiation to treat celiac plexus-associated pain.

2026 Annual American College of Radiation Oncologists (ACRO) Summit

, Michael Buckstein, MD, presented on the benefits and feasibility of using radiation to treat celiac plexus-associated pain. The presentation was based upon results from a phase 2 trial published in 

Buckstein, a radiation oncologist, as well as an associate professor, assistant program director and vice chair for Education at Mount Sinai Hospital, spoke with CancerNetwork® at ACRO based on his presentation. The discussion underscored the importance of the topic and where this technique may hopefully evolve to in the next 5 years.

What was the rationale for your presentation on using radiation for celiac plexus-associated pain?

This presentation is for a large audience for a trial that was just published last year. The lead on that trial was Yaacov Lawrence, MA, MBBS, MRCP, from Israel, and it was a revolutionary trial in the sense of providing an important service in terms of treating pancreatic-related pain or celiac plexus-related pain. Its adoption [might be] limited [because] it's somewhat scary to do and somewhat challenging to do. This is just a great platform from ACRO, as they told me to publicize this to a larger audience. To hopefully help implement it in more individuals' clinics.

What are the key takeaways from your presentation?

There are 3 big takeaways. The first thing that every clinician knows is that celiac plexus-related cancer pain is a real thing. Honestly, anyone in practice who treats any kind of [gastrointestinal] malignancies knows this is a real thing and that the current standards that we have to treat it are not adequate. The second is that this novel, somewhat intimidating, but actually very easy to implement, radiation protocol using very high-dose radio surgery of 25 Gy in a single fraction was proven to be effective. It's quite easy to do. The third thing of the talk is that I try to walk the audience through some of the pitfalls in implementation: What are some of the problems that I had when I was doing this as part of the one of the centers enrolled in this protocol, and what they can do to hopefully help bring this to their patient and deliver this very important service to a very important clinical population.

What clinical characteristics or diagnostic findings help you identify which patients are candidates for this?

Everyone knows that pancreatic cancer presents with painless jaundice, but number 2 is the patient's hunched over. They have epigastric pain and pain radiating through the back. That's the tell-tale sign. They present with that and usually go through a series of clinical investigations, just ruling out the usual causes of epigastric pain, like [gastroesophageal reflux disease], and then it presents with that. The pain usually gets a little better with chemotherapy, and then just comes back. It always comes back, and it's present both in metastatic patients and in localized patients.

How do outcomes with this technique compare with other supportive measures?

The standards of care right now for celiac-related pain are usually narcotics. There's always some level of narcotics you can get to where a patient becomes pain-free, but it obviously comes at a huge cost of [adverse] effects. And then celiac plexus blocks, which are woefully inadequate in my experience, and I think in almost everyone's experience. This trial was a positive trial in the sense that it produced a reduction in a validated pain scale by a significant number of points. More than 50% of patients had a response to the therapy, and a reduction in opioid use at 6 weeks was significantly positive for patients who received the celiac plexus radiation block vs standard, and what we normally would expect in the standard population. It was very encouraging.

How do patients typically tolerate the procedure?

One of the beauties of the procedure was that it was well thought-out by this group in Israel who originated this protocol, in that they decided to do this in as few treatments as possible. The regional plan was 5, and they went down to 1. It involves just 2 visits for the patient. They have to come in for a simulation, and they have to come in for a treatment. They get heavily pre-medicated during that treatment and afterwards to minimize toxicity and [adverse] effects in the acute setting from that. Patients tolerate it quite well.

What’s your preferred radiation planning and delivery technique?

You have to use some type of modulated therapy. One of the biggest problems we had in the US and continue to have is that insurance companies still don't want to pay for it, so using the classic codes of [stereotactic radiosurgery] or [stereotactic body radiation therapy] is off the table at this point unless you have a very permissive insurance company. But you can use [intensity-modulated radiation therapy (IMRT)] codes. So if you're willing, you can convince your billing department that that's okay. You can deliver this with a single fraction of IMRT; the planning is the same, the setup is the same. You don't have to go crazy with 4D simulations and gating and the typical advanced radiation metrics that were not used for the majority of patients, and just treat. I think it can be done.

What operational challenges did you face when implementing this into your practice?

Quite frankly, the hardest one was insurance blockades. So these are patients who are sick; they have weeks or months to live usually, and you're offering them at least a potential treatment, and they are frustrated that they're not getting on the machine because the insurance companies are blocking it. Their referring physicians are getting frustrated. Everything was frustrating. It's gotten better since now we have a publication showing the positive results. It is in the NCCN guidelines at this point, so it'll make it much easier. But that was by far the number one in the frustration levels. Some of the technicalities of learning how to do it [were obstacles]. It's scary. Giving 25 Gy in a single fraction, whether you're doing the brain or anywhere, it's a very serious dose. But the way the protocol is designed brilliantly is that it keeps toxicity to a very low level.

How might this technique evolve over the next 3 to 5 years?

Platforms like this at ACRO will be a way to publicize to a larger audience and community that this is available. They shouldn't be afraid to do it. It's an important service, and I expect it to hopefully pick up as one of the options. Again, patients and physicians are very frustrated. You're watching someone not only die from a horrible cancer because it's hard to treat, and patients generally would succumb to their disease, but they shouldn't do it in pain. If you have a service to offer them, it's quite amazing.

What makes this protocol so unique as well is that it doesn't treat the tumor per se; it treats the celiac plexus, or the nerve plexus itself, with radiation. The same way that radiation has now been found to be effective for treating VTAC [ventricular tachycardia], you're basically doing a neuroablation; the high dose of radiation in this context, you're treating that. You have an option of treating the tumor as well on the protocol. But the beauty of that was that it treats the nerves where the source of the pain is, and it also then allows you to spare the bowel from radiation exposure, because you aren't treating the tumor itself. That novelty is a game changer, because it's a very strange concept for radiation oncologists to think about: giving radiation to an off-target site, essentially, or a semi-off-target site in this particular context. That's what makes it so unique and different: that you're treating an actual nerve plexus. And it works.

Lawrence YR, Miszczyk M, Dawson LA, et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. 

. 2024;25(8):1070-1079. doi:10.1016/S1470-2045(24)00223-7

Articles

How Does Radiation Alleviate Celiac Plexus-Associated Pain?

Frontline Multiple Myeloma Therapy: Kicking the Can Further Down the Road?  The multiple myeloma field may have even better treatment options available by the time some patients experience disease recurrence years down the line.

Usmani 1to1 Video 29

 and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) among adults with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant. In a conversation with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, FASCO, detailed the clinical implications of this regulatory decision. Specifically, he discussed strategies for sequencing the newly approved daratumumab-based regimen with other lines of therapy for patients with multiple myeloma.

According to Usmani, the goal of frontline multiple myeloma therapies, which usually consist of quadruplet regimens, is to quickly produce a deep response in the first 4 or 6 months of treatment before spreading out subsequent dosing in the maintenance setting. Helping patients achieve an early remission, he said, may prevent the disease from recurring until years down the line, affirming the goal of “kick[ing] that can” of disease as far as one can.

Usmani is a myeloma specialist, cellular therapist, and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center. He is also a member of the International Myeloma Foundation’s Scientific Advisory Board.

The frontline treatment approaches, now, for a majority of patients would be a quadruplet regimen, unless we have frail patients. The idea is that [in] the initial part of treatment for the first 4 or 6 months, we try to get patients into a deeper response quicker, while managing the [adverse] effects from the treatments. From that perspective, that exposure to the quadruplet is for a fixed duration of time. Then, patients move on to a maintenance period where they’re getting less frequent treatments and [fewer] drugs.

From a treatment schema standpoint, that would be important. If we are able to get a majority of patients into good remissions that last for 4 or 5 plus years, for any patients being diagnosed in 2026, we’re essentially pushing off any potential chances of disease coming back to 2032 or 2033. By that time, we are going to have [better] treatment options for our patients if the disease comes back. That’s the goal: kick that can of the disease, the likelihood of [it] coming back, as [far] down the line as possible.

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. News release. FDA. January 27, 2026. Accessed February 9, 2026. https://tinyurl.com/47r6r8xf

Videos

The multiple myeloma field may have even better treatment options available by the time some patients experience disease recurrence years down the line.

Frontline Multiple Myeloma Therapy: Kicking the Can Further Down the Road? 

Among 13 patients treated with RB-1355, only 3 treatment-related adverse effects were observed in 2 patients, none of which were grade 3 or higher.

RB-1355 monotherapy or in combination with radiotherapy demonstrated safety, tolerability, and preliminary efficacy among patients with B- and T-cell lymphomas, according to an oral presentation of the phase 1 first-in-human trial given at the 

Specifically, among 13 patients treated with RB-1355, only 3 treatment-related adverse effects (AEs) were observed in 2 patients, none of which were grade 3 or higher. The events included a cytomegalovirus reaction, injection site reaction, and cytokine release syndrome (CRS).

Additionally, no dose-limiting toxicities or any immune-related AEs after a median follow-up of 104 days were observed in the trial (range, 30-365). Moreover, the grade 1 CRS event was resolved with nonsteroidal anti-inflammatory drugs within 1 hour; however, it was reported twice in the same patient. This patient, treated at the dose level of 300 x 10

 cells, would later develop a durable complete response at 8 months of follow-up.

Regarding efficacy, 2 patients with diffuse large B-cell lymphoma (DLBCL) treated in the high-dose cohorts, one with and the other without external radiation therapy at 2.5 Gy, experienced a complete response among 12 evaluable patients. Moreover, a partial response was observed in 2 patients, both treated in the low-dose cohort with radiotherapy, and 3 patients experienced stable disease. An antilymphoma response was noted in 75% of patients.

“These early results are very encouraging and shine a light on how we can harness the power of the body’s immune system in a new way when treating patients,” Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and presenting author of the trial, said in a news release on the study findings.

 “This approach has the potential to open a new pathway for challenging lymphoma cases and patients who do not have effective treatments available to them.”

Patients in the phase 1 study were enrolled across 3 US centers and received 3 intravenous RB-1355 injections across 5 days, with a target enrollment of 12. No lymphodepletion was required prior to receipt of the investigational agent. Those eligible for enrollment had diagnosed B- or T-cell non-Hodgkin lymphoma relapsed or refractory to at least 2 prior lines of systemic therapy. Additionally, they were required to have at least 1 needle-accessible lesion between 1.5 and 5.0 cm in diameter and an ECOG performance status of 0 to 2.

The median age in the study was 63 years (range, 36-81), and 92% of patients were men. Most patients had an ECOG performance status of 0 (85%), had cutaneous T-cell lymphoma (38%) or DLBCL (23%), and had received 4 or more prior lines of therapy (62%).

The primary end point of the trial was to establish the safety and tolerability of RB-1355 and to determine the recommended phase 2 dose. Exploratory end points included preliminary antitumor activity, immune correlates, and repeat dosing regimens.

Additional findings revealed a strong correlation between response and fold change in intratumoral proliferating T cells (

= .019) as well as between response and posttreatment ratio of intratumoral M1(CXCL9):M2(SPP1) macrophages (

Strati disclosed consulting relationships with AbbVie-Genmab, ADC Therapeutics, AstraZeneca-Acerta, BeOne, Incyte, Ipsen, Kite/Gilead, Lilly, Novartis, Roche-Genentech, and Sobi as well as having received research funds from ADC Therapeutics, ALX Oncology, AstraZeneca-Acerta, and Sobi.

Strati P, Feldman T, Kidder K, et al. Intratumoral cellular therapy with autologous M1 SIRPαlow macrophages in NHL: clinical results from a FIH phase 1 study. Abstract presented at: 2026 Transplantation & Cellular Therapy Meetings of American Society for Transplantation and Cellular Therapy and Center for International Blood and Marrow Transplant Research; February 4-7, 2026; Salt Lake City, UT. Abstract 76.

First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma. News release. The University of Texas MD Anderson Cancer Center. February 7, 2026. Accessed February 9, 2026. https://tinyurl.com/2s3srtsy

Confirmed antilymphoma responses occurred in 75% of patients with lymphoma, including 2 with a complete response and 2 with a partial response.

RB-1355 Is Safe and Well Tolerated in B- and T-Cell Lymphomas

Supporting results for zenocutuzumab in patients with 

 fusion–positive CCA come from the phase 1/2 eNRGy trial.

Zenocutuzumab-zbco (Bizengri) has received orphan drug designation from the FDA for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma (CCA), according to a press release from the developer, Partner Therapeutics, Inc.

 The designation represents a regulatory milestone for the bispecific antibody, which is designed to block the HER2-HER3 receptor axis driven by these rare oncogenic alterations.

This designation follows the FDA granting 

 to zenocutuzumab for the same patient population in October 2025, a decision supported by data from the phase 2 eNRGy trial (NCT02912949).

agent previously received accelerated approval

 in December 2024 for the treatment of adults with advanced 

 fusion–positive non–small cell lung cancer and pancreatic ductal adenocarcinoma.

Efficacy results from the CCA cohort of the eNRGy trial demonstrate meaningful clinical activity for zenocutuzumab in this hard-to-treat population.

 Among 19 evaluable patients with advanced 

-positive CCA, the investigator-assessed overall response rate was 37%. The clinical benefit rate was 58%.

The median duration of response was 7.4 months (95% CI, 4.6-not evaluable), whereas the median time to response was 1.9 months. In terms of survival outcomes, the median progression-free survival was 9.2 months (95% CI, 3.9-11.4). Tumor marker analysis also supported these findings, with all 16 patients with evaluable CA 19-9 data experiencing a decline in serum levels, including a 50% or greater reduction in 69% of cases.

“Patients with cholangiocarcinoma [have] a particularly aggressive cancer with poor prognosis and limited treatment options,” stated Juan W. Valle, MBChB, chief medical officer of the Cholangiocarcinoma Foundation, in the press release.

 “Receiving orphan drug designation for zenocutuzumab in patients with CCA harboring the 

 gene fusion is a significant regulatory milestone for Partner Therapeutics and highlights the urgent need for new and effective treatment options for patients with this disease.”

The global, open-label phase 1/2 eNRGy trial is evaluating the safety and antitumor activity of zenocutuzumab across several 

 fusion–positive solid tumor cohorts. The treatment regimen consists of zenocutuzumab administered at the recommended phase 2 dose of 750 mg via intravenous infusion every 2 weeks until disease progression or unacceptable toxicity.

Eligibility criteria required patients to have histologically or cytologically confirmed advanced unresectable or metastatic solid tumors harboring an 

 gene fusion as identified by comprehensive molecular profiling, specifically DNA- or RNA-based next-generation sequencing. Patients were required to have at least 1 measurable lesion per RECIST v1.1 guidelines, an ECOG performance status of 0 to 2, and an age of at least 18 years. All patients had either already received prior treatment or were unable to receive standard therapy.

The safety profile of zenocutuzumab was generally manageable and consistent with the overall study population. Most treatment-emergent adverse effects (TEAEs) were grade 1 or 2. Grade 3 or 4 TEAEs included anemia (14%), hypomagnesemia (9%), and increased γ-glutamyl transferase levels (9%).

The prescribing information for zenocutuzumab includes a boxed warning for embryo-fetal toxicity, and patients are further advised of the potential for lung inflammation and heart dysfunction.

 fusions represent a rare but actionable driver in [CCA], and the data from the eNRGy trial continue to highlight the potential of zenocutuzumab to offer meaningful clinical benefit for these patients,” study investigator Alison M. Schram, MD, a gynecologic medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, stated in a press release at the time of the breakthrough therapy designation.

Zenocutuzumab‑zbco receives FDA orphan drug designation for treatment of cholangiocarcinoma. News release. Partner Therapeutics Inc. February 5, 2026. Accessed February 9, 2026. https://tinyurl.com/ymstnwkw

Zenocutuzumab-zbco granted FDA breakthrough therapy designation for NRG1+ cholangiocarcinoma; data highlighting potential of zenocutuzumab-zbco in NRG1+ cholangiocarcinoma to be presented at AACR-NCI-EORTC. News release. October 24, 2025. Accessed February 9, 2026. https://tinyurl.com/3f8883ys

Schram AM, Cleary JM, Arnold D, et al. Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: analysis from the phase 2 eNRGy trial. 

 2025;24(suppl 10):A102. doi:10.1158/1535-7163.TARG-25-A102

Supporting results for zenocutuzumab in patients with NRG1 fusion–positive CCA come from the phase 1/2 eNRGy trial.

FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma

Supporting data for the designation came from the phase 1/2 KYANITE-1 trial (NCT06228326), in which KB707 demonstrated meaningful antitumor activity among patients with heavily pretreated advanced NSCLC.

The FDA has granted regenerative medicine advanced therapy (RMAT) designation to KB707, an investigational replication-defective herpes simplex virus type 1 (HSV-1)–based immunotherapy, for patients with advanced or metastatic non–small cell lung cancer (NSCLC), according to a press release from the developer, Krystal Biotech, Inc.

Supporting data for the designation came from the phase 1/2 KYANITE-1 trial (NCT06228326), in which KB707 demonstrated meaningful antitumor activity among patients with heavily pretreated advanced NSCLC. Investigators presented findings from the KYANITE-1 trial at the 

2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Among 11 evaluable patients with NSCLC, partial responses were observed in 3 patients at the time of abstract data cutoff and 4 patients at the time of extended follow-up. Data showed an objective response rate (ORR) of 27% and 36% during each respective period.

Safety findings among 39 patients with solid tumors revealed that treatment-related adverse effects (TRAEs) were typically grade 1 or 2 and transient. Investigators observed no grade 4/5 TRAEs, and 66.7% (n = 26) of patients experienced at least 1 TRAE. The most common TRAEs of any grade included chills (25.6%), cytokine release syndrome (23.1%), fatigue (20.5%), and influenzalike illness (15.4%).

“The FDA’s decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with inhaled KB707 in patients with advanced NSCLC. This is the second RMAT designation granted to a Krystal program and, as such, we know firsthand the benefits that this designation can provide to accelerate development and shorten the path to a potential approval,” Suma Krishnan, president of research and development at Krystal Biotech, stated in the press release.

 “We are excited to work closely with the FDA to maximize the potential impact of our KB707 program for patients with NSCLC.”

Developers designed KB707 as an HSV-1–based vector encoding human IL-12 and IL-2. The investigational gene therapy can deliver high doses of cytokines to the local tumor microenvironment.

In the open-label, dose-escalation, and dose-expansion phase 1/2 trial, 16 patients with at least 1 measurable lung lesion at screening were assigned to receive KB707 at 10

 plaque-forming units (PFU) as part of the dose-escalation portion whereas 23 patients received the agent at 10

The trial also includes a combination therapy cohort, which was enrolling at the time of the presentation at ASCO. Here, patients with histologically or cytologically confirmed stage III or IV NSCLC will receive KB707 plus pembrolizumab (Keytruda) with or without chemotherapy.

The trial’s primary end point was the safety and tolerability of KB707 based on AEs.

 Secondary end points included dose-limiting toxicities and preliminary efficacy based on ORR.

Patients 18 years or older with an ECOG performance status of 0 or 1, at least 1 measurable lesion per RECIST v1.1 criteria, histologically confirmed advanced solid tumor malignancies affecting the lungs, and progression on prior standard-of-care therapy were eligible for enrollment in the trial. Those who had not fully recovered from prior surgery or radiotherapy and patients with HIV-positive status were ineligible for study entry.

The median age was 64 years (range, 20-80) in the solid tumor population and 71 years (range, 54-77) in the NSCLC efficacy-evaluable population. In the NSCLC cohort, most patients had an ECOG performance status of 1 (90.9%), stage IV disease (100%), PD-L1–negative disease (45.5%), and 1 line of prior immunotherapy (63.6%).

Krystal Biotech announces RMAT designation granted by FDA to KB707 for the treatment of advanced or metastatic non-small cell lung cancer. News release. Krystal Biotech Inc. February 9, 2026. Accessed February 9, 2026. https://tinyurl.com/3y3rn3eb

Ma WW, McKean M, Villaruz LC, et al. Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: efficacy and safety results from a phase 1/2 study. 

2025;43(suppl 16):2575. doi:10.1200/JCO.2025.43.16_suppl.2575

A study assessing KB707 for the treatment of advanced solid tumor malignancies affecting the lungs (KYANITE-1). ClinicalTrials.gov. Updated October 24, 2025. Accessed February 9, 2026. https://tinyurl.com/4rtdej7a

Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC

In a conversation with CancerNetwork®, Manoj Bhasin, PhD, MS, spoke about findings from a study in which he and colleagues developed a single-cell atlas characterizing the dysregulation of the bone marrow immune microenvironment in newly diagnosed multiple myeloma. Findings published in 

showed that the immune system has a broad, treatment-independent influence on outcomes in newly diagnosed multiple myeloma.

Bhasin began by detailing the background and methodology of his study, in which an Immune Atlas of multiple myeloma helped generate profiles of 1,397,272 single cells from the bone marrow of 337 patients with newly diagnosed disease to characterize immune and hematopoietic cell populations. He also broke down specific analyses of certain aspects of the immune microenvironment, such as signaling evaluations demonstrating active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen potentially associated with tumor growth and survival.

Looking ahead, Bhasin described a need to research additional factors, including those beyond the bone marrow, which may help clinicians further optimize therapeutic strategies for patients with multiple myeloma.

“Maybe the biggest thing we want to say from this study is that the immune system is a critical player in the outcome of multiple myeloma, its emergence, and its therapeutic response. It is not a byproduct; it is a major driver of the outcomes,” Bhasin stated. “[Not] all high-risk multiple myeloma lesions are the same. We should look at the immune imprints of them, further comprehensively study them, and then help in designing immune therapies that fix the immune dysregulation that is associated with each cytogenetic alteration [instead of] thinking that all high-risk cytogenetic lesions of myeloma are all the same.”

Bhasin is a professor in the Department of Pediatrics and in the Department of Biomedical Informatics at Emory University School of Medicine, and director of Genomics, Proteomics, Bioinformatics and Systems Biology and the Aflac Director of the Single Cell Biology Program at Children’s Healthcare of Atlanta.

Pilcher WC, Yao L, Gonzalez-Kozlova E, et al. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. 

2026;7:224-246. doi:10.1038/s43018-025-01072-4

Podcasts

The immune system is a “critical player” in the emergence and outcome of multiple myeloma, according to Manoj Bhasin, PhD, MS.